# A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

> clinical trial · VERIFIED · 2026-08-13

Status: RECRUITING · Sponsor: Allist Pharmaceuticals, Inc. · Condition: Non-small Cell Lung Cancer

- Company: Allist Pharmaceuticals, Inc.
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT05276726

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.